Oncostatin M mediates STAT3-dependent intestinal epithelial restitution via increased cell proliferation, decreased apoptosis and upregulation of SERPIN family members

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Beigel, Florian ^a   Friedrich, Matthias ^a,b   Probst, Corina ^a   Sotlar, Karl ^b   Göke, Burkhard ^a   Diegelmann, Julia ^a,b   Brand, Stephan ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; GLYCOPROTEIN GP 130; LEUKEMIA INHIBITORY FACTOR RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; ONCOSTATIN M; ONCOSTATIN M RECEPTOR; ONCOSTATIN M RECEPTOR BETA; PROTEIN KINASE B; SERINE PROTEINASE INHIBITOR; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; STAT6 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE 1; STAT3 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CACO 2 CELL LINE; CELL MIGRATION; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CELL STRAIN DLD 1; CELL STRAIN SW480; COLON BIOPSY; COLORECTAL CANCER; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; ENZYME ACTIVITY; GENE EXPRESSION; HCT116 CELL LINE; HT 29 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BOWEL DISEASE; INTESTINE EPITHELIUM CELL; MICROARRAY ANALYSIS; MULTIGENE FAMILY; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS; UPREGULATION; BIOSYNTHESIS; FEMALE; INTESTINE MUCOSA; MALE; METABOLISM; PATHOLOGY; WOUND HEALING;

APOPTOSIS; CACO-2 CELLS; CELL PROLIFERATION; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MALE; ONCOSTATIN M; SERPINS; STAT3 TRANSCRIPTION FACTOR; UP-REGULATION; WOUND HEALING;

EID: 84899412960     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093498     Document Type: Article

References (64)

1. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, et al. (2012) Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491: 119-124.
2. Paul-Pletzer K (2006) Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders. Drugs Today (Barc) 42: 559-576.
3. Neurath MF, Finotto S (2011) IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 22: 83-89.
4. Taga T (1997) The signal transducer gp130 is shared by interleukin-6 family of haematopoietic and neurotrophic cytokines. Ann Med 29: 63-72.
5. Thoma B, Bird TA, Friend DJ, Gearing DP, Dower SK (1994) Oncostatin M and leukemia inhibitory factor trigger overlapping and different signals through partially shared receptor complexes. J Biol Chem 269: 6215-6222. (Pubitemid 24243012)
6. Mosley B, De Imus C, Friend D, Boiani N, Thoma B, et al. (1996) Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J Biol Chem 271: 32635-32643. (Pubitemid 27008685)
7. Tanaka M, Miyajima A (2003) Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol 149: 39-52.
8. Dumas A, Lagarde S, Laflamme C, Pouliot M (2011) Oncostatin M decreases interleukin-1beta secretion by human synovial fibroblasts and attenuates an acute inflammatory reaction in vivo. J Cell Mol Med 16: 1274-1285.
9. Fearon U, Mullan R, Markham T, Connolly M, Sullivan S, et al. (2006) Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures. Arthritis Rheum 54: 3152-3162. (Pubitemid 44622086)
10. Matthews VB, Knight B, Tirnitz-Parker JE, Boon J, Olynyk JK, et al. (2005) Oncostatin M induces an acute phase response but does not modulate the growth or maturation-status of liver progenitor (oval) cells in culture. Exp Cell Res 306: 252-263. (Pubitemid 40692788)
11. Richards CD, Brown TJ, Shoyab M, Baumann H, Gauldie J (1992) Recombinant oncostatin M stimulates the production of acute phase proteins in HepG2 cells and rat primary hepatocytes in vitro. J Immunol 148: 1731-1736.
12. Sanchez AL, Langdon CM, Akhtar M, Lu J, Richards CD, et al. (2003) Adenoviral transfer of the murine oncostatin M gene suppresses dextran-sodium sulfate-induced colitis. J Interferon Cytokine Res 23: 193-201. (Pubitemid 36528982)
13. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125: 279-284. (Pubitemid 33000466)
14. Thomas PD, Campbell MJ, Kejariwal A, Mi H, Karlak B, et al. (2003) PANTHER: a library of protein families and subfamilies indexed by function. Genome Res 13: 2129-2141. (Pubitemid 37161770)
15. Muehlhoefer A, Saubermann LJ, Gu X, Luedtke-Heckenkamp K, Xavier R, et al. (2000) Fractalkine is an epithelial and endothelial cell-derived chemoattractant for intraepithelial lymphocytes in the small intestinal mucosa. J Immunol 164: 3368-3376. (Pubitemid 30149003)
16. Dignass AU, Podolsky DK (1993) Cytokine modulation of intestinal epithelial cell restitution: central role of transforming growth factor beta. Gastroenterology 105: 1323-1332. (Pubitemid 23315306)
17. Schreiber S, Rosenstiel P, Hampe J, Nikolaus S, Groessner B, et al. (2002) Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut 51: 379-385.
18. Diegelmann J, Olszak T, Goke B, Blumberg RS, Brand S (2012) A novel role for IL-27 as mediator of intestinal epithelial barrier protection mediated via differential STAT signaling and induction of antibacterial and anti-inflammatory proteins. J Biol Chem.
19. Woo JK, Choi Y, Oh SH, Jeong JH, Choi DH, et al. (2011) Mucin 1 enhances the tumor angiogenic response by activation of the AKT signaling pathway. Oncogene 26: 2187-2198.
20. Benko S, Magalhaes JG, Philpott DJ, Girardin SE (2010) NLRC5 limits the activation of inflammatory pathways. J Immunol 185: 1681-1691.
21. Nagaishi T, Chen Z, Chen L, Iijima H, Nakajima A, et al. (2008) CEACAM1 and the regulation of mucosal inflammation. Mucosal Immunol 1 Suppl 1: S39-42.
22. Roda G, Dahan S, Mezzanotte L, Caponi A, Roth-Walter F, et al. (2009) Defect in CEACAM family member expression in Crohn's disease IECs is regulated by the transcription factor SOX9. Inflamm Bowel Dis 15: 1775-1783.
23. Kugathasan S, Baldassano RN, Bradfield JP, Sleiman PM, Imielinski M, et al. (2008) Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease. Nat Genet 40: 1211-1215.
24. Nosaka T, Kawashima T, Misawa K, Ikuta K, Mui AL, et al. (1999) STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J 18: 4754-4765. (Pubitemid 29415529)
25. Migita K, Komori A, Torigoshi T, Maeda Y, Izumi Y, et al. (2011) CP690,550 inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoid synoviocytes. Arthritis Res Ther 13: R72.
26. Boniface K, Diveu C, Morel F, Pedretti N, Froger J, et al. (2007) Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation. J Immunol 178: 4615-4622. (Pubitemid 46492414)
27. Hoffmann DC, Textoris C, Oehme F, Klaassen T, Goppelt A, et al. (2011) Pivotal role for alpha1-antichymotrypsin in skin repair. J Biol Chem 286: 28889-28901.
28. Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, et al. (1997) Regulation of neuronal survival by the serine-threonine protein kinase Akt [see comments]. Science 275: 661-665. (Pubitemid 27061332)
29. Fridell YW, Jin Y, Quilliam LA, Burchert A, McCloskey P, et al. (1996) Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase. Mol Cell Biol 16: 135-145. (Pubitemid 126506959)
30. Battle TE, Frank DA (2002) The role of STATs in apoptosis. Curr Mol Med 2: 381-392. (Pubitemid 35452886)
31. Camilleri M, Madsen K, Spiller R, Greenwood-Van Meerveld B, Verne GN (2012) Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol Motil 24: 503-512.
32. Kanda J, Uchiyama T, Tomosugi N, Higuchi M, Kawabata H (2009) Oncostatin M and leukemia inhibitory factor increase hepcidin expression in hepatoma cell lines. Int J Hematol 90: 545-552.
33. Weiss TW, Speidl WS, Kaun C, Rega G, Springer C, et al. (2003) Glycoprotein 130 ligand oncostatin-M induces expression of vascular endothelial growth factor in human adult cardiac myocytes. Cardiovasc Res 59: 628-638. (Pubitemid 38368679)
34. Hohensinner PJ, Kaun C, Rychli K, Niessner A, Pfaffenberger S, et al. (2009) The inflammatory mediator oncostatin M induces stromal derived factor-1 in human adult cardiac cells. FASEB J 23: 774-782.
35. Mozaffarian A, Brewer AW, Trueblood ES, Luzina IG, Todd NW, et al. (2008) Mechanisms of oncostatin M-induced pulmonary inflammation and fibrosis. J Immunol 181: 7243-7253.
36. Rega G, Kaun C, Weiss TW, Demyanets S, Zorn G, et al. (2005) Inflammatory cytokines interleukin-6 and oncostatin m induce plasminogen activator inhibitor-1 in human adipose tissue. Circulation 111: 1938-1945. (Pubitemid 40570213)
37. Boutten A, Venembre P, Seta N, Hamelin J, Aubier M, et al. (1998) Oncostatin M is a potent stimulator of alpha1-antitrypsin secretion in lung epithelial cells: modulation by transforming growth factor-beta and interferon-gamma. Am J Respir Cell Mol Biol 18: 511-520. (Pubitemid 128353624)
38. Wahl AF, Wallace PM (2001) Oncostatin M in the anti-inflammatory response. Ann Rheum Dis 60 Suppl 3: iii75-80. (Pubitemid 32980451)
39. Waetzig GH, Seegert D, Rosenstiel P, Nikolaus S, Schreiber S (2002) p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J Immunol 168: 5342-5351. (Pubitemid 34496003)
40. Hommes D, van den Blink B, Plasse T, Bartelsman J, Xu C, et al. (2002) Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 122: 7-14. (Pubitemid 34049188)
41. Bonacchi A, Romagnani P, Romanelli RG, Efsen E, Annunziato F, et al. (2001) Signal transduction by the chemokine receptor CXCR3: activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes. J Biol Chem 276: 9945-9954.
42. Brand S, Dambacher J, Beigel F, Olszak T, Diebold J, et al. (2005) CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. Exp Cell Res: In press.
43. Brand S, Sakaguchi T, Gu X, Colgan SP, Reinecker HC (2002) Fractalkine-mediated signals regulate cell-survival and immune-modulatory responses in intestinal epithelial cells. Gastroenterology 122: 166-177. (Pubitemid 34049205)
44. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, et al. (2006) IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol 290: G827-838.
45. Brand S, Hofbauer K, Dambacher J, Schnitzler F, Staudinger T, et al. (2006) Increased expression of the chemokine fractalkine in Crohn's disease and association of the fractalkine receptor T280M polymorphism with a fibrostenosing disease Phenotype. Am J Gastroenterol 101: 99-106. (Pubitemid 43381715)
46. Brand S, Olszak T, Beigel F, Diebold J, Otte JM, et al. (2006) Cell differentiation dependent expressed CCR6 mediates ERK-1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of colorectal cancer cells. J Cell Biochem 97: 709-723.
47. Brand S, Dambacher J, Beigel F, Olszak T, Diebold J, et al. (2005) CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. Exp Cell Res 310: 117-130. (Pubitemid 41393693)
48. McLoughlin RM, Jenkins BJ, Grail D, Williams AS, Fielding CA, et al. (2005) IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc Natl Acad Sci U S A 102: 9589-9594. (Pubitemid 40981725)
49. Pickert G, Neufert C, Leppkes M, Zheng Y, Wittkopf N, et al. (2009) STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med 206: 1465-1472.
50. Diegelmann J, Olszak T, Goke B, Blumberg RS, Brand S (2012) A novel role for IL-27 as mediator of intestinal epithelial barrier protection mediated via differential STAT signaling and induction of antibacterial and anti-inflammatory proteins. J Biol Chem 2: 286-298.
51. Pineton de Chambrun G, Peyrin-Biroulet L, Lemann M, Colombel JF (2010) Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 7: 15-29.
52. Shin SH, Han SK, Jeong SH, Kim WK (2012) Potential of Oncostatin M to accelerate diabetic wound healing. Int Wound J.
53. Nakamura K, Nonaka H, Saito H, Tanaka M, Miyajima A (2004) Hepatocyte proliferation and tissue remodeling is impaired after liver injury in oncostatin M receptor knockout mice. Hepatology 39: 635-644. (Pubitemid 38337643)
54. Brown TJ, Lioubin MN, Marquardt H (1987) Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes. Synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells. J Immunol 139: 2977-2983. (Pubitemid 17157467)
55. Brand S (2009) Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 58: 1152-1167.
56. Bouma G, Strober W (2003) The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 3: 521-533. (Pubitemid 37328672)
57. Dambacher J, Beigel F, Zitzmann K, De Toni EN, Goke B, et al. (2009) The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut 58: 1207-1217.
58. Dambacher J, Beigel F, Seiderer J, Haller D, Goke B, et al. (2007) Interleukin 31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease. Gut 56: 1257-1265. (Pubitemid 47300428)
59. de Koning PJ, Kummer JA, de Poot SA, Quadir R, Broekhuizen R, et al. (2011) Intracellular serine protease inhibitor SERPINB4 inhibits granzyme M-induced cell death. PLoS ONE 6: e22645.
60. Vidalino L, Doria A, Quarta S, Zen M, Gatta A, et al. (2009) SERPINB3, apoptosis and autoimmunity. Autoimmun Rev 9: 108-112.
61. Calabrese F, Lunardi F, Giacometti C, Marulli G, Gnoato M, et al. (2008) Overexpression of squamous cell carcinoma antigen in idiopathic pulmonary fibrosis: clinicopathological correlations. Thorax 63: 795-802.
62. Quarta S, Vidalino L, Turato C, Ruvoletto M, Calabrese F, et al. (2010) SERPINB3 induces epithelial-mesenchymal transition. J Pathol 221: 343-356.
63. Lannan EA, Galliher-Beckley AJ, Scoltock AB, Cidlowski JA (2012) Proinflammatory actions of glucocorticoids: glucocorticoids and TNFalpha coregulate gene expression in vitro and in vivo. Endocrinology 153: 3701-3712.
64. Uchiyama K, Naito Y, Takagi T, Mizushima K, Hirai Y, et al. (2012) Serpin B1 protects colonic epithelial cell via blockage of neutrophil elastase activity and its expression is enhanced in patients with ulcerative colitis. Am J Physiol Gastrointest Liver Physiol 302: G1163-1170.